Research just published in the British Journal of Clinical Pharmacology shows a sudden increase in reports immediately after each of the three programmes were aired in the UK in October 2002, May 2003 and October 2004.
Five regulatory announcements made in the UK during the same period resulted in a much smaller five per cent increase in reports of adverse reactions.
The research team from the Department of Social Medicine at Bristol University, UK, explored prescribing patterns and adverse drug reports for paroxetine, which is part of a group of drugs called SSRIs (selective serotonine reuptake inhibitors).
"Our analysis of adverse drug reports made by doctors suggests that negative publicity, particularly the three Panorama programmes, were associated with marked, short-term peaks in reporting" says lead author Dr Richard Martin.
"In the months before and after the three Panorama programmes were aired adverse reports went up from 8.3 to 13.4 per 100,000 prescriptions. The change before and after regulatory announcements went from 7.6 to 8.0."
SSRI's are used to treat patients with depression. They work by raising levels of the important chemical serotonin which helps to regulate communications (electrical activity) in the regions of the brain thought to be affected by depression.
The initial Panorama programme followed two announcements by the US Food and Drug Administration. The first announcement, in January 2002, warned of severe withdrawal symptoms from paroxetine and the second, in October 2002, suggested links between the drug and suicidal behaviour.
"Overall prescribing of paroxetine started to fall gradually after the FDA's warning was publicised in the UK" adds Dr Martin. "Prescribing patterns were not as obviously affected by media attention and regulatory announcements as the reporting of adverse drug reactions, but they may have helped to maintain the decline."
Panorama is the BBC's award-winning flagship current affairs programme. First broadcast in 1953, it is the longest-running public affairs TV programme in the world.
The programme has won numerous awards, including a Mental Health Media Award in 2003 for its first two investigations into the safety of paroxetine (Seroxat).
"The documentaries showed just how powerful the voice of mental health service users and survivors can be, fuelling furious public and media debate whilst demonstrating that broadcasters can both sensitively and successfully reach and touch the lives of the wider public" said the Mental Health Media Award.
Dr Martin agrees that the programmes had an impact and says that the research carried out by the team at Bristol University shows clearly how the programmes had a marked effect on the reporting of adverse effects of paroxetine.
However, the effect of the programmes on reporting was only short term, highlighting the importance of continued efforts to improve the way adverse drug reactions to widely prescribed drugs are monitored.
For further information and a press copy of the full paper please contact
Annette Whibley, Wizard Communications
wordwizard@clara.co.uk
To interview Dr Richard Martin please contact
Dr Cherry Lewis, University of Bristol
0117 928 8086 / 07729 421885 / cherry.lewis@bristol.ac.uk
Notes to editors
www.blackwellpublishing.com/bjcp
Journal
British Journal of Clinical Pharmacology